Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus GemOx in relapsed or refractory classical Hodgkin lymphoma
ChiCTR2000033441Phase 4Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, gemcitabine and oxaliplatin in classical Hodgkin lymphoma (cHL), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Best complete remission rate. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
tislelizumabgemcitabineoxaliplatin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on ChiCTR2000033441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033441.